Author:
Gori S,Colozza M,Mosconi A M,Franceschi E,Basurto C,Cherubini R,Sidoni A,Rulli A,Bisacci C,Angelis V De,Crinò L,Tonato M
Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. Baselga J, Tripathy D, Mendelson J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. J Clin Oncol 14: 737–744
2. Burris III HA, Hainswoth JD, Mirand FT (2000) Phase II trial on Herceptin induction followed by combination therapy with paclitaxel and carboplatin: a Minnie Pearl Research Network Trial. Breast Cancer Res Treat 64: 31 (abstract 24)
3. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnel CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP (2001) Clinical activity of trastuzumab and vinorelbine in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 19: 2722–2730
4. Carbonell X, Castaneda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Baselga J (2002) Efficacy and safety of 3-weekly Hereceptin in women with HER2-positive metastatic breast cancer: preliminary data from a phase II study. Proc Am Soc Clin Oncol 21: 19a (abstract 73)
5. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic breast cancer. J Clin Oncol 17: 2639–2648
Cited by
50 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献